Synergistic inhibition of survival, proliferation, and migration of U87 cells with a combination of LY341495 and Iressa

• Published in: PloS one Vol. 8; no. 5; p. e64588
• Main Authors: Yelskaya, Zarina, Carrillo, Vangie, Dubisz, Ewa, Gulzar, Hira, Morgan, Devon, Mahajan, Shahana S
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 27.05.2013; Public Library of Science (PLoS)
• Subjects: Amino Acids - pharmacology; Antineoplastic Agents - pharmacology; Apoptosis; Apoptosis - drug effects; Biology; Breast cancer; Cancer therapies; Cell adhesion & migration; Cell growth; Cell Line, Tumor; Cell migration; Cell Movement - drug effects; Cell proliferation; Cell Proliferation - drug effects; Cell survival; Cell Survival - drug effects; Combinatorial analysis; Dose-Response Relationship, Drug; Drug Synergism; Drugs; Epidermal growth factor; Epidermal growth factor receptors; Glioblastoma; Glioblastoma - metabolism; Glutamic Acid - metabolism; Glutamic Acid - pharmacology; Glutamic acid receptors (metabotropic); Health sciences; Humans; Inhibitors; Kinases; Medical prognosis; Medicine; Phosphorylation; Propionic acid; Proteins; Quinazolines - pharmacology; Riluzole - pharmacology; Rodents; Synergistic effect; Xanthenes - pharmacology; α-Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid; New York; United States > US

Glioblastomas exploit various molecular pathways to promote glutamate- dependent growth by activating the AMPA (2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl) propanoic acid) receptor, the group II metabotropic glutamate receptor, mGluR, and the epidermal growth factor receptor, EGFR. We hypothesized...